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69

Abstract

70 Defining causal variation by fine-mapping can be more effective in multi-ethnic genetic

71 studies, particularly in regions such as the MHC with highly population-specific

72 structure. To enable such studies, we constructed a large (N=21,546) high resolution HLA

73 reference panel spanning five global populations based on whole-genome sequencing

74 data. Expectedly, we observed unique long-range HLA haplotypes within each population

75 group. Despite this, we demonstrated consistently accurate imputation at G-group

76 resolution (94.2%, 93.7%, 97.8% and 93.7% in Admixed African (AA), East Asian (EAS),

77 European (EUR) and Latino (LAT)). We jointly analyzed genome-wide association studies

78 (GWAS) of HIV-1 viral load from EUR, AA and LAT populations. Our analysis pinpointed

79 the MHC association to three amino acid positions (97, 67 and 156) marking three

80 consecutive pockets (C, B and D) within the HLA-B peptide binding groove, explaining

81 12.9% of trait variance, and obviating effects of previously reported associations from

82 population-specific HIV studies.

83

Main

84 The HLA genes located within the MHC region encode proteins that play essential roles in
85 immune responses including antigen presentation. They account for more heritability than all
86 other variants together for many diseases1–4. It also has more reported GWAS trait associations
87 than any other locus5. The extended MHC region spans 6Mb on chromosome 6p21.3 and
88 contains more than 260 genes6. Due to population-specific positive selection it harbors
89 unusually high sequence variation, longer haplotypes than most of the genome, and haplotypes
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90 that are specific to individual ancestral populations7,8. Consequently, the MHC is among the
91 most challenging regions in the genome to analyze. Advances in HLA imputation have enabled
92 population-specific association and fine-mapping studies of this locus2,9–12. But despite large
93 effect sizes, fine-mapping in multiple populations simultaneously is challenging without a single
94 large and high-resolution multi-ethnic reference panel. This has caused confusion in some
95 instances. For example, defining the driving HLA alleles may inform the design of antigenic
96 peptides for vaccines13,14 for HIV-1, which led to 770,000 deaths in 2018 alone15. However,
97 multiple risk HLA risk alleles have been independently reported in different populations1,10,16, and
98 it is not clear if they represent truly population-specific signals or are confounded by linkage.

99

100

Results
Performance evaluation of inferred classical HLA alleles

101 To build a large-scale multi-ethnic HLA imputation reference panel, we used high-coverage
102 whole genome sequencing (WGS) datasets17–21 from the Japan Biological Informatics
103 Consortium20, the BioBank Japan Project18, the Estonian Biobank22, the 1000 Genomes Project
104 (1KG)21 and a subset of studies in the TOPMed program (Supplementary Note,
105 Supplementary Table 1-2). To perform HLA typing using WGS data, we extracted reads
106 mapped to the extended MHC region (chr6:25Mb-35Mb) and unmapped reads from 24,338
107 samples. We applied a population reference graph23–25, for the MHC region to infer classical
108 alleles for three HLA class I genes (HLA-A, -B and -C) and five class II genes (HLA-DQA1,
109 -DQB1, -DRB1, -DPA1, -DPB1) at G-group resolution, which determines the sequences of the
110 exons encoding the peptide binding groove. We required samples to have >20x coverage

111 across all HLA genes (Supplementary Table 1, 3). After quality control our panel included
112 21,546 individuals: 10,187 EUR, 7,849 AA, 2,069 EAS, 952 LAT and 489 SAS.
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113 To assess the accuracy of the WGS HLA allele calls, we compared the inferred HLA classical
114 alleles to gold standard sequence-based typing (SBT) in 955 1KG subjects and 288 Japanese
115 subjects and quantified concordance. In both cohorts we observed slightly higher average
116 accuracy for class I genes, obtaining 99.0% (one-field, formally known as two-digit), 99.2%
117 (amino acid) and 96.5% (G-group resolution), than class II genes, obtaining 98.7% (one-field),
118 99.7% (amino acid) and 96.7% (G-group resolution, Methods, Supplementary Figure 1,
119 Supplementary Tables 4-5, Extended Data 1).

120

HLA diversity

121 To quantify MHC diversity, we calculated identity-by-descent (IBD) distances26 between all
122 individuals using 38,398 MHC single nucleotide polymorphisms (SNPs) included in the
123 multi-ethnic HLA reference panel (N=21,546) and applied principal component analysis (PCA,
124 Methods). PCA distinguished EUR, EAS and AA as well as the admixed LAT and SAS samples
125 (Figure 1a, Supplementary Figure 2). This reflected widespread HLA allele frequency
126 differences between populations (Figure 1b-c, Supplementary Figure 3). Of 130 unique

127 common (frequency > 1%) G-group alleles, 129 demonstrated significant differences of
128 frequencies across populations (4 degree-of-freedom Chi-square test, p-value < 0.05/130,
129 Supplementary Figure 4). The only exception was DQA1*01:01:01G which was nominally
130 significant (unadjusted p-value = 0.047). These differences may be related to adaptive selection.
131 For example, the B*53:01:01G allele is enriched in Admixed Africans (11.7% in AA versus 0.3%
132 in others) and it has been previously associated with malaria protection27,28. Consistent with
133 previous reports29,30, we observed that HLA-B had the highest allelic diversity (n=443) while
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134 HLA-DQA1 had the least (n=17, Supplementary Figure 5-6, Supplementary Table 6,
135 Extended Data 1).

136 To understand the haplotype structure of HLA between pairs of HLA genes we calculated a
137 multiallelic linkage disequilibrium (LD) measurement index31–33,

ε , which is 0 when there is no

138 LD and 1 when there is perfect LD (Figure 2a). We observed higher

ε between DQA1, DQB1,

139 and DRB1; between DPA1 and DPB1; and between B and C (Supplementary Figure 7). The
140 heterogeneity between different populations was underscored by the presence of
141 population-specific common (frequency >1%) high resolution long-range haplotypes
142 (HLA-A~C~B~DRB1~DQA1~DQB1~DPA1~DPB1, Figure 2b, Supplementary Figure 8-12,
143 Extended Data 2, Methods). The most common within-population haplotype was A24::DP6
144 (HLA-A*24:02:01G~C*12:02:01G~B*52:01:01G~DRB1*15:02:01G~DQA1*01:03:01G~DQB1*06
145 :01:01G~DPA1*02:01:01G~DPB1*09:01:01G) found at a frequency of 3.61% in EAS
146 (Supplementary Figure 8). This haplotype is strongly associated with immune-mediated traits
147 such as HIV34 and ulcerative colitis35 in Japanese individuals. The next most common haplotype
148 was the well-described European-specific ancestral haplotype A1::DP1 or 8.136,37 (
149 frequency=2.76%,
150 HLA-A*01:01:01G~C*07:01:01G~B*08:01:01G~DRB1*03:01:01G~DQA1*05:01:01G~DQB1*02:
151 01:01G~DPA1*02:01:02G~DPB1*01:01:01G, Supplementary Figure 9). This haplotype is
152 associated with diverse immunopathological phenotypes in the European population, including
153 systemic lupus erythematosus38, myositis39 and several other conditions36. We observed

154 long-range haplotypes in admixed populations including A1::DP4 in SAS (frequency=1.86%,

155 Supplementary Figure 10), A30::DP1 in AA (frequency=1.18%,
156 HLA-A*30:01:01G~C*17:01:01G~B*42:01:01:G~DRB1*03:02:01G~DQA1*04:01:01G~DQB1*04
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157 :02:01G~DPA1*02:02:02G~DPB1*01:01:01G , Supplementary Figure 11), and A29::DP11 in
158 LAT (frequency=0.74%,
159 HLA-A*29:02:01G~C*16:01:01G~B*44*03:01:G~DRB1*07:01:01G~DQA1*02:01:01G~DQB1*0
160 2:01:01G~DPA1*02:01:01G~DPB1*11:01:01G, Supplementary Figure 12).
161 These haplotypes also have associations with multiple diseases: for example C*06:02~B*57:01
162 is associated with psoriasis40 and A*30:01~C*17:01~B*42:01 is associated with HIV41.

163

HLA selection signature

164 Previous studies have suggested that recent natural selection favors African ancestry in the
165 HLA region in admixed populations42–45. To test this hypothesis in our data, we obtained WGS
166 data from a subset of individuals within two admixed populations (1,832 AA and 594 LAT,
167 determined by the first three global principal components, Supplementary Figure 13,
168 Supplementary Note). Admixed individuals have genomes that are a mosaic of different
169 ancestries. If genetic variations or haplotypes from an ancestral population are advantageous,
170 then they are under selection and are expected to have higher frequency than by chance. Using
171 ELAI46, we quantified how much the ancestry proportions differed within the MHC from the
172 genome-wide average. In AA, we observed that the average genome-wide proportion of African
173 ancestry was 74.5%, compared to 78.0% in the extended MHC region, corresponding to a 3.42
174 (95% CI: 3.35-3.49) standard deviation increase. In LAT, we observed 5.76% African ancestry
175 genome-wide versus 16.0% in the extended MHC region, representing an increase of 4.23
176 (95% CI: 4.14-4.31) standard deviations (Methods, Supplementary Figure 14). To ensure our
177 results are robust to different local ancestry inference methods, we applied an alternative
178 method called RFMix47 and observed a similarly consistent MHC-specific excess of African
179 ancestry in LAT, and also an excess in AA that was more modest (Supplementary Figure 14).
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180

Construction of a multi-ethnic HLA reference panel and its performance evaluation

181 Next, we constructed a multi-ethnic HLA imputation reference panel based on classical HLA
182 alleles and 38,398 genomic markers in the extended MHC region using a novel HLA-focused
183 pipeline HLA-TAPAS (HLA-Typing At Protein for Association Studies). Briefly, HLA-TAPAS can
184 handle HLA reference panel construction (MakeReference); HLA imputation (SNP2HLA) and
185 HLA association (HLAassoc) (Methods, URLs). Compared to a widely used HLA reference
186 panel with European-only individuals (The Type 1 Diabetes Genetics Consortium48 , T1DGC),
187 this new reference panel has a six-fold increase in the number of observed HLA alleles and
188 non-HLA genomic markers (Supplementary Table 7). We noted the difference in observed
189 classical HLA alleles is mainly due to the inclusion of diverse populations rather than its size;
190 after downsampling the reference panel to be the same size as T1DGC (N=5,225), there was
191 still a three-fold increase in observed alleles (Figure 3a).

192 To empirically assess imputation accuracy of our reference panel, we first used the publicly
193 available gold-standard HLA types (HLA-A, -B,-C, -DRB1 and -DQB1) of 1,267 diverse samples
194 from AA, EAS, EUR and LAT included in 1KG. We removed 955 overlapping samples within the
195 reference panel, and to ensure a representative analysis we kept 6,007 markers overlapping
196 with the Global Genotyping Array SNPs. Across the five genes, the average G-group resolution
197 accuracies were 94.2%, 93.7%, 97.8% and 93.7% in AA, EAS, EUR and LAT (Figure 3b-c,
198 Supplementary Table 8, Methods, Extended Data 3). Compared to the T1DGC panel, our
199 multi-ethnic reference panel showed the most improvement for individuals of non-European
200 descent; we obtained 4.27%, 2.96%, 2.90% and 1.05% improvement at G-group resolution for
201 AA, EAS, LAT, and EUR individuals, respectively (Figure 3d). Increased diversity was
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202 responsible for the improvement; downsampling the reference panel be the same size as the
203 T1DGC panel still yielded superior performance (Figure 3d). To validate our panel further, we
204 imputed HLA alleles into a multi-ethnic cohort of 2,291 individuals from the Genotype and
205 Phenotype (GaP) registry genotyped on the ImmunoChip array. We obtained SBT HLA type
206 information for six classical class I and class II loci (HLA-A, -B, -C, -DQA1, -DQB1, -DRB1) in 75
207 samples with diverse ancestral background (25 EUR, 25 EAS and 25 AA, Supplementary
208 Figure 15, Methods). Average accuracies were 99.0%, 95.7% and 97.0% for EUR, EAS and
209 AA respectively when comparing SBT HLA alleles at G-group resolution (Methods, Extended
210 Data 3). Similar to the 1KG analysis, the multi-ethnic reference panel showed significant
211 improvement for individuals with non-European descent (6.3% and 11.1% improvement for EAS
212 and African individuals respectively at G-group resolution), and a more modest 2% improvement
213 in EUR (Supplementary Figure 16, Supplementary Table 9).

214

Fine-mapping causal variants of HIV jointly in three populations in the MHC region

215 Next we investigated MHC effects within human immunodeficiency virus type 1 (HIV-1) set point
216 viral load. Upon primary infection with HIV-1, the set point viral load is reached after the immune

217 system has developed specific cytotoxic T lymphocytes (CTL) that are able to partially control

218 the virus. It has been well-established that the set point viral load (spVL) varies in the infected

219 population and positively correlates with rate of disease progression49. Previous studies
220 suggested that HIV-1 infection has a strong genetic component, and specific HLA class I alleles
221 explain the majority of genetic risk10,50. The existence of multiple independent, ancestry-specific,
222 risk-associated alleles has been reported in both European1,10 and African American16
223 populations. However, without a multi-ethnic reference panel it has not been possible to
224 determine if these signals are consistent across different ancestral groups.
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225 To define the MHC allelic effects shared across multiple populations, we applied our multi-ethnic
226 MHC reference panel to 7,445 EUR, 3,901 AA and 677 LAT HIV-1 infected subjects (Methods,
227 Supplementary Table 10). Imputation resulted in 640 classical HLA alleles, 4,513 amino acids
228 in HLA proteins and 49,321 SNPs in the extended MHC region for association and fine-mapping
229 analysis. We confirmed 96.6% imputation accuracy of two-field (or four-digit) resolution with a
230 minor allele frequency > 0.5% in this cohort by comparing imputed classical alleles to the SBT
231 alleles in a subset of 1,067 AA subjects16(Supplementary Figure 17, Extended Data 3).

232 We next tested SNPs, amino acid positions and classical HLA alleles across the MHC for
233 association to spVL. We performed this jointly in EUR, AA and LAT population using a linear
234 regression model with sex, principal components and ancestry as covariates (Methods). In
235 agreement with previous studies, we found the strongest spVL-associated classical HLA allele
236 is B*57 (effect size = -0.84, P binary = 8.68

× 10

144

). This corresponded to a single residue Val97

237 in HLA-B that tracks almost perfectly with B*57 ( r2 = 0.995 ) and showed the strongest
238 association of any single residue (effect size = -0.84, P binary = 5.99

× 10

145

, Supplementary

239 Figure 18).

240 Then to determine which amino acid positions have independent association with spVL, we
241 tested each of the amino acid positions by grouping haplotypes carrying a specific residue at
242 each position in an additive model2,9 (Methods). We found the strongest spVL-associated amino
243 acid variant in HLA-B is as previously reported1,10,16 at position 97 (Figure 4a-b, Supplementary
244 Table 11) which strikingly explains 9.06% of the phenotypic variance. Position 97 in HLA-B was
245 more significant ( P omnibus = 2.86

× 10

184

) than any single SNP or classical HLA allele, including
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246 B*57 (Supplementary Figure 18, Extended Data 4). Of the six allelic variants
247 (Val/Asn/Trp/Thr/Arg/Ser) at this position, the Val residue conferred the strongest protective
248 effect (effect size = -0.88, P = 9.32

× 10

152

, Supplementary Figure 19) relative to the most

249 common residue Arg (frequency = 47.8%). All six amino acid alleles have consistent
250 frequencies and effect sizes across the three population groups (Figure 5a-b, Supplementary
251 Figure 20).

252 We next wanted to test whether there were other independent effects outside of position 97 in
253 HLA-B. After accounting for the effects of amino acid 97 in HLA-B using a conditional haplotype
254 analysis (Methods), we observed a significant independent association at position 67 in HLA-B
255 ( P omnibus = 2.82

× 10

39

, Figure 4c-d, Supplementary Table 11). Considering this might be an

256 artifact of forward search, we exhaustively tested all possible pairs of polymorphic amino acid
257 positions in HLA-B. Of 7,260 pairs of amino acid positions, none obtained a better
258 goodness-of-fit than the pair of positions 97 and 67, which collectively explained 11.2% variance
259 in spVL (Figure 5e, Supplementary Table 12). At position 67, Met67 residue shows the most
260 protective effect (effect size = -0.44, P = 1.19

× 10

59

) among the five possible amino acids

261 (Cys/Phe/Met/Ser/Tyr) relative to the most common residue Ser (frequency =10.0%).

262 Conditioning on positions 97 and 67 revealed an additional association at position 156 in HLA-B
263 ( P omnibus = 1.92

× 10

30

, Figure 4e-f, Supplementary Table 11). In agreement with the

264 stepwise conditional analysis, when we tested all 287,980 possible combinations of three amino
265 acid positions in HLA-B, the most statistically significant combination of amino acids sites is 67,
266 97 and 156 ( P = 5.68

× 10

244

, Supplementary Table 13). These three positions explained

267 12.9% of the variance (Figure 5e). At position 156, residue Arg shows the largest risk effect
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268 (effect size = 0.180, P = 8.92

× 10

14

) among the four possible allelic variants

269 (Leu/Arg/Asp/Trp), relative to the most common residue Leu (frequency = 35.1%).

270 These amino acid positions mark three consecutive pockets within the HLA-B peptide-binding
271 groove (Figure 5c). Position 97 is located in the C-pocket and has an important role in

272 determining the specificity of the peptide-binding groove51,52. Position 67 is in the B-pocket, and

273 Met67 side chains occupy the space where larger B-pocket anchors reside in other

274 peptide-MHC structures; its presence limits the size of potential peptide position P2 side

275 chains52. Amino acid position 156 is part of the D-pocket and influences the conformation of the

276 peptide-binding region53. These results are consistent with the observation that in HLA-B*57, the

277 single most protective spVL-associated one-field allele (a single change at position 156 from

278 Leu → Arg or equivalently HLA-B*57:03 → HLA-B*57:02) leads to an increased repertoire of

279 HIV-specific epitope41,54.

280 Despite differences in the power to detect associations due to differences in allele frequencies
281 (Supplementary Figure 21), we observed generally consistent effects of individual residues
282 across populations (Figure 5d, Supplementary Figure 22-23, Supplementary Table 14).
283 There are 26 unique haplotypes defined by the amino acids at positions 67, 97 and 156 in
284 HLA-B (Table 1, Supplementary Table 15). When we tested for effect size heterogeneity by
285 ancestry for each of these haplotypes (Methods), we observed only 2 of 26 haplotypes showed
286 heterogeneity (F-test P-value < 0.05/26), possibly due to different interplay between genetic and
287 environmental variation at population-level. These results support the concept that these
288 positions mediate HIV-1 viral load in diverse ancestries.
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289 To assess whether there were other independent MHC associations outside HLA-B, we
290 conditioned on all amino acid positions in HLA-B and observed associations at HLA-A, including
291 at position 77 in HLA-A ( P omnibus = 9.10

× 10

7

292 classical HLA allele HLA-A*31 ( P binary = 2.45
293 P binary = 3.10

× 10

16

, Figure 4g-h, Supplementary Table 11), the

× 10 ) and the rs2256919 promoter SNP (
8

, Supplementary Figure 18). These associations argue for an effect at

294 HLA-A, but larger studies and functional studies will be necessary to define the driving effects.

295

Discussion

296 In our study we demonstrated accurate imputation with a single large reference panel for HLA
297 imputation. We have shown how this reference panel can be used to impute genetic variation at
298 eight HLA classical genes accurately across a wide range of populations. Accurate imputation in
299 multi-ethnic studies is essential for fine-mapping.

300 We showed the utility of this approach by defining the alleles that best explain HIV-1 viral load in
301 infected individuals. Our work implicates three amino acid positions (97, 67 and 156) in HLA-B
302 in conferring the known protective effect of HLA class I variation on HIV-1 infection. Combining
303 all alleles at these three positions explained 12.9% of the variance in spVL (Figure 5e). These
304 positions all fall within the peptide-binding groove of the respective MHC protein (Figure 5c),
305 indicating that variation in the amino acid content of the peptide-binding groove is the major
306 genetic determinant of HIV control. Supported by experimental studies54–57, positions highlighted
307 in our work indicated a structural basis for the HLA association with HIV disease progression
308 that is mediated by the conformation of the peptide within the class I binding groove. This result
309 highlights how a study with ancestrally diverse populations can potentially point to causal
310 variation by leveraging linkage disequilibrium difference between ethnic groups.
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311 We note that previous studies have shown position 97 in HLA-B has the strongest association
312 with HIV-1 spVL or case-control in African American and European populations, but highlighted
313 different additional signals via conditional analysis (position 45, 67 in HLA-B and position 77, 95
314 in HLA-A in Europeans1,10,16 and position 63, 116 and 245 in HLA-B in African Americans16).
315 These signals do not explain the signals we report here; after conditioning on positions 45, 63,
316 116, 245 of HLA-B and 95 of HLA-A, the association of the four identified amino acids identified
317 in this study remained significant ( P < 5

× 10

8

). In contrast, our binding groove alleles explain

318 these other alleles; conditioning on the four amino acid positions identified in this study
319 (positions 67, 97 and 156 in HLA-B), all previously reported positions did not pass the
320 significance threshold ( P > 5

× 10

8

, Supplementary Figure 24).

321 Furthermore, defining the effect sizes for HLA alleles across different populations is essential for
322 defining risk of a wide-range of diseases in the clinical setting. There is increasing application of
323 genome-wide genotyping by patients both by healthcare providers and direct-to-consumer
324 vendors. The large effects of the MHC region for a wide-range of immune and non-immune
325 traits, makes it essential to define HLA allelic effect sizes essential in multi-ethnic studies in
326 order to build generally applicable clinical polygenic risk scores for many diseases in diverse
327 populations58–61. Resources like the one we present here will be an essential ingredient in such
328 studies.
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329

Methods

330

Individuals included in the reference panel

331 Study participants were from the Jackson Heart Study (JHS , N = 3,027), Multi-Ethnic Study of

332 Atherosclerosis (MESA, N=4,620), Chronic Obstructive Pulmonary Disease Gene (COPDGene)

333 study (N=10,623), Estonian Biobank (EST, N=2,244), Japan Biological Informatics Consortium

334 (JPN, N=295), Biobank Japan (JPN, N=1,025) and 1000 Genomes Project (1KG, N=2,504).

335 Each study was previously approved by respective institutional review boards (IRBs), including

336 for the generation of WGS data and association with phenotypes. All participants provided

337 written consent. Further details of cohort descriptions and phenotype definitions are described in

338 the Supplementary Note.

339

HLA-TAPAS

340 HLA-TAPAS (HLA-Typing At Protein for Association Studies) is an HLA-focused pipeline that
341 can handle HLA reference panel construction (MakeReference), HLA imputation (SNP2HLA),
342 and HLA association (HLAassoc). It is an updated version of the SNP2HLA48 to build an
343 imputation reference panel, perform HLA classical allele, amino acid and SNP imputation within
344 the extended MHC region. Briefly, major updates include (1) using PLINK1.9 (URLs) instead of
345 v1.07; (2) using BEAGLE v4.1 (URLs) instead of v3 for phasing and imputation; and (3)
346 including custom R scripts for performing association and fine-mapping analysis at amino acid
347 level in multiple ancestries. The source code is available for download (URLs).
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348

Construction of a multi-ethnic HLA reference panel using whole-genome

349

sequences

350 To construct a multi-ethnic HLA imputation reference panel, we used 24,338 whole-genome
351 sequences at different depths (Supplementary Table 1). Details of the construction using
352 deep-coverage whole-genome sequencing are described in the Supplementary Note. Briefly,
353 alignment and variant-calling for genomes sequenced by each cohort were performed
354 independently. We performed local realignment and quality recalibration with the Genome
355 Analysis Toolkit62 (GATK; version 3.6) on Chromosome 6:25,000,000-35,000,000. We detected
356 single nucleotide variants (SNV) and indels using GATK with HaplotypeCaller. To eliminate
357 false-positive sites called in the MHC region, we restrict our panel to SNVs reported in 1000
358 Genomes Project21 only.

359 We next inferred classical HLA alleles at G-group resolution for eight classical HLA genes
360 (HLA-A, -B, -C, -DQA1, -DQB1, -DRB1, -DPA1 and -DPB1) using a population reference
361 graph24,25. To extend the reference panel versatility, we inferred amino acid variation, one-field
362 and two-field resolution alleles from the inferred G-group alleles. After removing samples with
363 low-coverage and failed genome-wide quality control (Supplementary Table 3), we constructed
364 a multi-ethnic HLA imputation reference panel (N=21,546) using the HLA-TAPAS
365 MakeReference module (URLs, Method).
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366

Sequence-based typing of HLA alleles

367 Purified DNA from the 75 donors from the GaP registry (at the Feinstein Institute for Medical
368 Research) was sent to NHS Blood and Transplant, UK, where HLA typing was performed.
369 Next-generation sequencing was done for HLA-A, -B, -C, -DQB1, -DPB1 and -DRB1.
370 PCR-sequence-specific oligonucleotide probe sequencing was performed for HLA-DQA1 in all
371 samples. These typing methods yielded classical allele calls for seven genes at three-field
372 (HLA-A, -B, -C and -DQB1) or G-group resolution (HLA-DQA1, -DPB1 and -DRB1).

373 Genomic DNA from the 288 unrelated samples of Japanese ancestry underwent high-resolution
374 allele typing (three-field alleles) of six classical HLA genes (HLA-A, -B and -C for class I; and
375 HLA-DRB1, -DQA1 and -DPB1 for class II)20.

376 The 1000 Genomes panel consists of 1,267 individuals with information on five HLA genes
377 (HLA-A, -B, -C, -DQB1, and -DRB1) at G-group resolution among four major ancestral groups
378 (AA, EAS, EUR and LAT)7.

379 We obtained HLA typing of the 1,067 African American subjects included in the HIV-1 viral load
380 study as described previously16,63. Briefly, seven classical HLA genes (HLA-A, -B, -C, -DQA1,
381 -DQB1 -DRB1 and -DPB1) were obtained by sequencing exons 2 and 3 and/or single-stranded
382 conformation polymorphism PCR, and was provided at two-field resolution.
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383

Accuracy measure between inferred and sequence-based typing HLA

384

genotypes

385 Allelic variants at HLA genes can be typed at different resolutions: one-field HLA types specify
386 serological activity, two-field HLA types specify the amino acids encoded by the exons of the
387 HLA gene, and three-field types determine the full exonic sequence including synonymous
388 variants. G-group resolution determines the sequences of the exons encoding the peptide
389 binding groove, that is, exons 2 and 3 for class I and exon 2 class II genes. Thus, any

390 polymorphism occurring in exon 4 of class I gene or exon 3 of class II gene was not defined.

391 This means many G-group alleles can map to multiple three-field and two-field HLA alleles.

392 We calculated the accuracy at each HLA gene by summing across the dosage of each correctly
393 inferred HLA allele or amino acid across all individuals (N), and divided by the total number of
394 observations (2*N). That is,
N

395

Accuracy(g) =

∑ Di (A1I,g )+Di (A2i,g )
i

2N

,

396 where Accuracy(g) represents the accuracy at a classical HLA gene (e.g. HLA-B). Di
397 represents the inferred dosage of an allele in individual i , and alleles A1i,g and A2i,g represent
398 the true (SBT) HLA types for an individual i .

399 To evaluate the accuracy between the inferred and validated HLA types obtained from SBT at
400 G-group resolution, we translated the highest resolution specified by the validation data to its
401 matching G-group resolution based IMGT/HLA database (e.g. HLA-A*01:01 →
402 HLA-A*01:01:01G), and compared it to the primary output from HLA*LA or HLA-TAPAS. We
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403 also translated all G-group alleles to their matching amino acid sequences, and compared them
404 against the validation alleles, we referred to this as the amino acid level.

405 To evaluate imputation performance in individual classical HLA alleles and amino acids, we
406 calculated the dosage r2 correlation between imputed and SBT dosage.

407 r2 =

[

N

∑ xi y i

i=1

 ( ∑ x )( ∑ y ) /N ] /
N

i=1

2

N

i

i=1

i

[(

N

∑ xi

i=1

2

 ( ∑ x ) /N
2

N

i=1

i

)(

N

∑ yi

i=1

2

 ( ∑ y ) /N
2

N

i=1

i

)]

,

408 where xi and y i represents the inferred and SBT dosage of an allele in individual i . N
409 represents the number of individuals.

410

Principal component analysis

411 We performed a principal component analysis of the MHC region based on the
412 identity-by-descent (IBD) distances between all 21,809 individuals included in the multi-ethnic
413 reference panel. We computed the IBD distance using Beagle (Version 4.1, URLs) and
414 averaged over 100 runs with all variants (54,474) included in the HLA reference panel. Due to
415 uneven representation of different ethnicity groups (Supplementary Table 2), we applied a
416 weighted PCA approach, where mean and standard deviation of the IBD matrix within an
417 ethnicity group are weighted inversely proportional to the sample size.

418

HLA haplotype frequency estimation

419 We applied an expectation-maximization algorithm approach implemented in Hapl-o-Mat64
420 (URLs) to estimate HLA haplotype frequency based on eight classical HLA alleles inferred at
421 G-group resolution. We estimated haplotype frequencies both overall and within five continental
422 populations (Extended Data 2).
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423

Local ancestry inference

424 To detect local ancestry in admixed samples, we first applied ELAI46 to chromosome 6 with 1000
425 Genomes Project21 as the reference panel. We extracted 63,998 common HapMap3 SNPs
426 between the WGS (MESA cohort) and the 1000 Genome reference panel. We used the same
427 set of SNPs for ELAI and RFMix analysis. We applied ELAI46 to 1,832 African Americans and
428 594 Latinos. For 1,832 African American individuals included in the study, we used genotypes of
429 99 CEU and 108 YRI in the 1000 Genome Project as reference panel, assuming admixture
430 generation to be seven generations ago. We used two upper-layer clusters and 10 lower-layer
431 clusters in the model. For Latinos, we selected 65 Latinos with Native American (NAT) ancestry
432 > 75% included in the 1000 Genomes Project identified using the ADMIXTURE analysis65 and
433 used these individuals with high NAT, as well as CEU and YRI from 1000 Genomes as
434 reference panels. We assumed that the admixture time was 20 generations ago. For ELAI, we
435 used three upper-layer clusters and 15 lower-layer clusters in the model.

436 To address the technical concerns that local ancestry methods are biased by the high LD of
437 MHC region66,67, we performed an alternative method, RFMix47, for local ancestry inference that
438 accounts for high LD and lack of parental reference panels. Similar deviation from genome-wide
439 ancestry was observed using RFMix (Supplementary Figure 14), indicating that the selection
440 signals we observed here are robust to different inference methods.
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441

HLA imputation in the HIV-1 viral load GWAS data in three populations

442 We used genome-wide genotyping data from 12,023 HIV-1 infected individuals aggregated
443 across more than 10 different cohorts (Supplementary Table 10). The details of these samples
444 and quality control procedures have been described previously10,68. Using the HIV-1 viral load
445 GWAS data, we extracted the genotypes of SNPs located in the extended MHC region
446 (chr6:28-34Mb, Supplementary Table 10). We conducted genotype imputation of one-field,
447 two-field and G-group classical HLA alleles and amino acid polymorphisms of the eight class I
448 and class II HLA genes using the constructed multi-ethnic HLA imputation reference panel and
449 the HLA-TAPAS pipeline.

450 After imputation, we obtained the genotypes of 640 classical alleles, 4,513 amino acid positions
451 of the eight classical HLA genes, and 49,321 SNPs located in the extended MHC region. We

452 excluded variants with MAF < 0.5% and imputation r2 < 0.5 for all association studies. In total,
453 we tested 51,358 variants in our association and fine-mapping study.

454

HLA association analysis

455 For the HIV-1 viral loads of EUR, AA and LAT samples, we conducted a joint haplotype-based
456 association analysis using a linear regression model under the assumption of additive effects of
457 the number of HLA haplotypes for each individual. Phased haplotypes at a locus (i.e., HLA
458 amino acid position) were constructed from the phased imputed genotypes of variants in the
459 locus (i.e., amino acid change or SNP) and were converted to a haplotype matrix where each
460 row is observed haplotypes (in the locus), not genotypes.
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461 For each amino acid position, we applied a conditional haplotype analysis. We tested a
462 multiallelic association between the HIV-1 viral load and a haplotype matrix (of the position) with
463 covariates, including sex, study-specific PCs, and a categorical variable indicating a population.
464 That is
465

m 1



C

i

j

y = β 0 + ∑ β 1i xi + ∑ β 2j cj ,

466 where xi is the amino acid haplotype formed by each of the m amino acid residues that occur at
467 that position, and cj are the covariates included in the model.

468 To get an omnibus P-value for each position, we estimated the effect of each amino acid by
469 assessing the significance of the improvement in fit by calculating the in-model fit, compared to
470 a null model following an F-distribution with

degrees of freedom. This is implemented

471 using an ANOVA test in R as described previously32,69. The most frequent haplotype was
472 excluded from a haplotype matrix as a reference haplotype for association.

473 For the conditional analysis, we assumed that the null model consisted of haplotypes as

474 defined by residues at previously defined amino acid positions. The alternative model is in

475 addition of another position with m residues. We tested whether the addition of those amino

476 acid positions, and the creation of

additional haplotypes groups, improved on the previous

477 set. We then assessed the significance of the improvement in the delta deviance (sum of

478 squares) over the previous model using an F-test. We performed stepwise conditional analysis

479 to identify additional independent signals by adjusting for the most significant amino acid

480 position in each step until none met the significance threshold ( P = 5

22

× 10

8

). We restricted

medRxiv preprint doi: https://doi.org/10.1101/2020.07.16.20155606; this version posted July 18, 2020. The copyright holder for this preprint
Luo et
(which
wasal.
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

481 analysis to haplotypes that have a minimum of 10 occurrences within HLA-B, and removed any

482 individual with rare haplotypes for the conditional analysis.

483 For the exhaustive search, we tested all possible amino acid pairs and triplets for association.

484 For each set of amino acid positions, we used the groups of residues occurring at these

485 positions to estimate effect size and calculated for each of these models the delta deviance in

486 risk prediction and its p-values compared to the null model.

487

Heterogeneity testing of effect sizes

488 We used interaction analyses with models that included haplotype-by-ancestry (Haplotype x
489 Ancestry) interaction terms. The fit of nested models was compared to a null model using the
490 F-statistic with two degrees of freedom, for which the association interaction P-value indicated
491 whether the inclusion of the Haplotype x Ancestry interaction terms improved the model fit
492 compared to the null model that did not include the interaction terms. Interaction P-values for all
493 haplotypes formed by positions 97, 67 and 156 in HLA-B are listed in Supplementary Table 15.
494 Haplotypes that had a significant Bonferroni-corrected Haplotype x Ancestry interaction
495 heterogeneity P-value (P < 0.05/26) were considered to show evidence of significant effect size
496 heterogeneity between ancestries.

497

URLs

498 HLA-TAPAS, https://github.com/immunogenomics/HLA-TAPAS
499 IMGT/HLA, https://www.ebi.ac.uk/ipd/imgt/hla/;
500 GATK version 3.6, https://software.broadinstitute.org/gatk/download/archive;
501 HLA*LA, https://github.com/DiltheyLab/HLA-PRG-LA;
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502 PLINK 1.90, https://www.cog-genomics.org/plink2;
503 Beagle 4.1, https://faculty.washington.edu/browning/beagle/b4_1.html;
504 Hapl-o-Mat, https://github.com/DKMS/Hapl-o-Mat/;
505 1000 Genomes gold-standard HLA types,
506 http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/HLA_types/
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748

Figures

749 Figure 1. Global diversity of the MHC region. (a) Principal component analysis of the
750 pairwise IBD distance between 21,546 samples using MHC region markers. Allele diversity of
751 (b) HLA-B and (c) HLA-DQA1 among five continental populations (AA=Admixed African;
752 EUR=European; LAT=Latino; EAS=East Asian; SAS=South Asian). The top two most common
753 alleles within each population group are named, the remaining alleles are grouped as ‘others’.
754 (a)
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755 (b)

756 (c)

36

medRxiv preprint doi: https://doi.org/10.1101/2020.07.16.20155606; this version posted July 18, 2020. The copyright holder for this preprint
Luo et
(which
wasal.
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

757 Figure 2. Pairwise LD and haplotype structure for six classical HLA genes in five

ε

758 population groups. (a) shows the pairwise normalized entropy ( ) measuring the difference of
759 the haplotype frequency distribution for linkage disequilibrium and linkage equilibrium among
760 five population groups. It takes values between 0 (no LD) to 1 (perfect LD). (b) shows the
761 haplotype structures of the eight classical HLA genes in each population. The tile in a bar
762 represents an HLA allele, and its height corresponds to the frequencies of the HLA allele. The
763 gray lines connecting between two alleles represent HLA haplotypes. The width of these lines
764 corresponds to the frequencies of the haplotypes. The most frequent long-range HLA
765 haplotypes within each population is bolded and highlighted in a color described by the key at
766 the bottom.
767 (a)
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768 (b)
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769 Figure 3. The multi-ethnic HLA reference panel shows improvement in allele diversity and
770 imputation accuracy. (a). The number of HLA alleles at the two-field resolution included in the
771 multi-ethnic HLA reference panel (N = 21,546) compared to the European only Type 1 Diabetes
772 Genetics Consortium48 (T1DGC) panel (N = 5,225) as well as a subset of the multi-ethnic HLA
773 panel down-sampled to the same size as T1DGC. (b). The correlation between imputed and
774 typed dosages of classical HLA alleles using the multi-ethnic HLA reference panel at one-filed
775 (red), two-field (blue) and G-group resolution (black) of the 955 1000 Genomes subjects. (c).
776 The imputation accuracy for five classical HLA genes at one-field, two-field and G-group
777 resolution. (d). The imputation accuracy at G-group resolution of the 1000 Genomes subjects
778 stratified by four diverse ancestries when using three different imputation reference panels as
779 described in (a).
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780 Figure 4. Stepwise conditional analysis of the allele and amino acid positions of classical
781 HLA genes to HIV-1 viral load. Each circle point represents the linear regression -log10(
782 P binary ) for all classical HLA alleles. Each diamond point represents -log10( P omnibus ) for the
783 tested amino acid positions in HLA (blue=HLA-A; yellow=HLA-C; red=HLA-B;
784 lightblue=HLA-DRB1; green=HLA-DQA1; purple=HLA-DQB1, darkgreen=HLA-DPA1;
785 lightgreen=HLA-DPB1). Association at amino acid positions with more than two alleles was
786 calculated using a multi-degree-of-freedom omnibus test. The dashed blacked line represents

× 10

787 the significance threshold of P = 5

8

. Each panel shows the association plot in the process

788 of stepwise conditional omnibus test. (a) One-field classical allele B*57 ( P = 9.84
789 (b) amino acid position 97 in HLA-B ( P omnibus = 2.86

× 10

184

× 10

138

) and

) showed the strongest association

790 signal. Results conditioned on position 97 in HLA-B showed a secondary signal at (c) classical
791 allele B*81:0101:G ( P = 4.53

× 10

23

) and (d) position 67 in HLA-B ( P omnibus = 1.08

× 10

40

).

792 Results conditioned on position 97 and 67 in HLA-B showed the same classical allele (e)
793 B*81:0101G ( P = 2.70
794 P omnibus = 1.92

× 10

30

× 10

23

) and (f) third signal at position 156 in HLA-B (

). Results conditioned on position 97, 67 and 156 int HLA-B showed a

795 fourth signal at (g) HLA-A*31 ( P = 2.45
796 P omnibus = 5.35

× 10

7

× 10

8

) and (h) position 77 in HLA-A (

) outside HLA-B.
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797 Figure 5. Location and effect of three independently associated amino acid positions in
798 HLA-B. (a) Allele frequency of six residues at position 97 in HLA-B among three populations.
799 (b) Effect on spVL (i.e., change in log10 HIV-1 spVL per allele copy) of individual amino acid
800 residues at position 97 in HLA-B. Results were calculated per allele using linear regression
801 models, including gender and principal components within each ancestry as covariates. (c)
802 HLA-B (PDB ID code 2bvp) proteins. Omnibus and stepwise conditional analysis identified three
803 independent amino acid positions (positions 97 (red), 67 (orange), and 156 (green) in HLA-B.
804 (d) Effect on spVL (i.e., change in log10 HIV-1 spVL per allele copy) of individual amino acid
805 residues at each position reported in this and previous work10,16. Results were calculated per
806 allele using linear regression models. The x-axis shows the effect size and its standard errors in
807 the joint analysis, and the y-axis shows the effect size and its standard error in individual
808 populations (purple = Admixed American; blue = European and orange = Latino). (e) Variance of
809 spVL explained by the haplotypes formed by different amino acid positions.
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810

Tables

811 Table 1. Effect estimates for the haplotypes defined by the three independent amino
812 acids in HLA-B associated with HIV-1 viral load. Only haplotypes with >1% frequency in the
813 overall population are listed (Supplementary Table 15). Classical alleles of HLA-B are grouped
814 based on the amino acid residues presented at position 97, 67 and 156 in HLA-B. For each
815 haplotype, the multivariate effect is given as an effect size, taking the most frequent haplotype
816 (97R-67S-156L) as the reference (effect size = 0). Heterogeneity p-value (P(het)) of each
817 haplotype is calculated using a F-statistics with two degrees of freedom (Methods). Effect size
818 and its standard error in each population are listed only for haplotypes that show evidence of
819 heterogeneity (P-value < 0.05 /26, bolded). Unadjusted haplotype frequencies are given in each
820 population.
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